Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melphalan, Carboplatin, and Etoposide with BBBD for Oligodendroglioma
NCT00303849Phase 2Completed
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Sep 2005
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of melphalan in anaplastic oligodendroglioma (AO) and oligoastrocytoma, sponsored by OHSU Knight Cancer Institute. Started Sep 2005; status: completed.
02
Drugs
melphalan
03
Conditions
anaplastic oligodendroglioma (AO)oligoastrocytoma
Beyond the preview
Go deeper on NCT00303849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00303849.